Sulfasalazine

CHEMBL421 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

398.4 g/mol

LogP

-0.7

Phase

4

Taken orally, this anti-inflammatory medication releases two active components in the colon — sulfapyridine and mesalazine — where they reduce the chronic inflammation driving conditions like Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is also being investigated for potential effects in certain cancers due to its ability to interfere with inflammatory signaling pathways.

น้ำหนักโมเลกุล

398.4000 g/mol

LogP

-0.70

TPSA

150.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Age-Related Macular Degeneration Respiratory Disease Rheumatoid Arthritis Migraine Generalized Anxiety Disorder Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Lymphoma Transplant Medicine Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O

InChI

InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+

Molecular Formula

C18H14N4O5S

HBD / HBA

3 / 9

พันธะที่หมุนได้

6

อะตอมหนัก

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Taken orally, this anti-inflammatory medication releases two active components in the colon — sulfapyridine and mesalazine — where they reduce the chronic inflammation driving conditions like Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is also being investigated for potential effects in certain cancers due to its ability to interfere with inflammatory signaling pathways.

Yes, Sulfasalazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL421. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5339. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Sulfasalazine บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C18H14N4O5S
คำพ้องความหมาย: 2

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.